Evofem Biosciences Acquires Lupin's US Women's Health Division

Lupin announced on Monday the sale of its US commercial women's health specialty business to Evofem Biosciences, a US-based biopharmaceutical firm dedicated to women's health. The transaction, for an undisclosed amount, underscores Lupin's strategic shift towards strengthening its US specialty business in synergistic therapeutic areas such as respiratory and neurological diseases. Lupin's US Commercial Women’s Health Specialty Business centers around the promotion of Solosec (secnidazole) oral granules. Solosec, an FDA-approved single-dose antimicrobial agent, offers a comprehensive treatment regimen for bacterial vaginosis (BV) and trichomoniasis, prevalent infections affecting sexual health.

The company mentioned that, “Under the terms of the deal, Lupin can receive a potential total consideration of up to $ 84 million based on future contingent milestones.” At the close of trading on Monday, Lupin's stock rose by 1.7% to Rs 1828.25 per share. The announcement was made post-market hours. Fabrice Egros, President of Global Corporate Development, Lupin said: “We are pleased to divest our US Commercial Women’s Health Specialty business, including Solosec, to Evofem.  This divestment is another step in aligning our US specialty business with our strategic plan to build our specialty business in therapeutic areas where we have building blocks of synergy. These include respiratory and neurological diseases.”